Summary & Overview
HCPCS J3470: Hyaluronidase Injection, Up to 150 Units
HCPCS Level II code J3470 denotes an injection of hyaluronidase, up to 150 units, a pharmaceutical agent used to increase tissue permeability and aid dispersion of other injected therapies. Nationally, this code is relevant across outpatient settings where injectable adjuncts are administered alongside therapeutic or diagnostic procedures. Reimbursement and billing practices for this drug impact outpatient drug management and procedural workflows.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations, common billing modifiers used with injectable drug administration, and payer-specific reimbursement patterns where available. The publication also outlines benchmarking context for pricing and utilization and summarizes clinical indications and service settings associated with hyaluronidase injection.
This summary equips billing managers, clinicians, and policy analysts with concise context for HCPCS Level II code J3470, highlighting where to expect variations in coverage and administrative practice and what topics are covered in greater detail in the full publication.
Billing Code Overview
HCPCS Level II code J3470 represents the administration of hyaluronidase injection, up to 150 units. This code describes a single injectable medication product used to increase tissue permeability, commonly used as an adjunct to facilitate dispersion and absorption of other injected drugs or fluids.
-
Service type: Drug administration (injectable medication)
-
Typical site of service: Outpatient clinic, physician office, ambulatory surgical center, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old adult presenting to an outpatient surgical clinic or ambulatory infusion center for enzymatic dispersion of subcutaneous or intradermal hyaluronic acid-containing filler or for assistance in enhancing tissue dispersion of other injected medications. The patient has persistent localized nodularity, migration, vascular compromise suspicion after cosmetic filler injection, or requires hyaluronidase to improve spread of a therapeutic injectate. The clinical workflow includes: pre-procedure assessment and informed consent, verification of indication and allergy status (particularly bee venom/latex if relevant), preparation of reconstituted hyaluronidase up to 150 units, aseptic administration into the affected tissue by a qualified clinician (dermatologist, plastic surgeon, or qualified proceduralist), observation for immediate adverse reaction, and documentation of units administered, lot number, and response. Typical sites of service are outpatient clinic, ambulatory surgical center, or office-based procedure rooms. Hospital inpatient use is uncommon but may occur for severe complications requiring monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work, time, or complexity substantially exceeds typical for the service when documenting justification for increased resources. |